A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Beijing Biotech
Incyte Corporation
Servier
Sumitomo Pharma America, Inc.
Curis, Inc.
Dana-Farber Cancer Institute
Auron Therapeutics, Inc.
Senti Biosciences
NextCure, Inc.
Prelude Therapeutics
Peking University People's Hospital
Geron Corporation
Thomas Jefferson University
M.D. Anderson Cancer Center
Ryvu Therapeutics SA
Celgene
University of Illinois at Chicago
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Servier
M.D. Anderson Cancer Center
Celgene
Aptose Biosciences Inc.
Stanford University
AbbVie
Cyclacel Pharmaceuticals, Inc.
University Health Network, Toronto
Mustang Bio
Newave Pharmaceutical Inc
Novartis
Novartis
Prelude Therapeutics
Prelude Therapeutics
Blueprint Medicines Corporation
Roswell Park Cancer Institute
University Hospital, Bordeaux
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Daiichi Sankyo
Rutgers, The State University of New Jersey
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
Roswell Park Cancer Institute
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Daiichi Sankyo
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center